MIST
Milestone·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MIST
Milestone Pharmaceuticals Inc.
A biopharmaceutical company that developing innovative cardiovascular medicines
1111 Dr. Frederik-Phillips Boulevard, Suite 420, Montreal, Quebec CA H4M 2X6
--
Milestone Pharmaceuticals Inc., was incorporated in 2003 under the laws of Quebec. The company is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular drugs. The company's lead product candidate, tripamide, is a new powerful calcium channel blocker that they designed as a fast-acting nasal spray for patients to self-administer. The company is developing tripamide for the treatment of specific arrhythmias, with the primary indication for the treatment of paroxysmal supraventricular tachycardia, or PSVT, followed by the treatment of atrial fibrillation with rapid ventricular rate, or AFIB-RVR.
Company Financials
EPS
MIST has released its 2025 Q3 earnings. EPS was reported at -0.12, versus the expected -0.17, beating expectations. The chart below visualizes how MIST has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
